FIELD: biotechnology.
SUBSTANCE: antibodies or antigen-binding fragments thereof that specifically bind to human TLR7 or monkey TLR7 and do not bind to mouse TLR7 or rat TLR7 are proposed. The antibodies inhibit the function of human TLR7 or monkey TLR7. The invention is also related to polynucleotides encoding antibodies or their antigen-binding fragments, expression vectors and host cells including said polynucleotides, a method for producing antibodies and their antigen-binding fragments.
EFFECT: present invention may find further application in treatment of diseases associated with immune inflammation.
27 cl, 31 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGAINST SIRPα | 2019 |
|
RU2791002C2 |
| ANTI-CDH6-ANTIBODY AND ANTI-CDH6-ANTIBODY-DRUG CONJUGATE | 2018 |
|
RU2798285C2 |
| ANTIBODY FOR TREATMENT OF AUTOIMMUNE DISEASES | 2017 |
|
RU2781148C2 |
| ANTIBODY AGAINST GPR20 AND ANTIBODY AGAINST GPR20-DRUG CONJUGATES | 2018 |
|
RU2772804C2 |
| ANTI-ORAI1 ANTIBODY | 2015 |
|
RU2724742C2 |
| Fc FUSION HIGH AFFINITY IgE RECEPTOR α-CHAIN | 2016 |
|
RU2715606C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATMENT AND/OR PREVENTION OF MALIGNANT TUMOR | 2017 |
|
RU2766586C2 |
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
